CELU vs. RPHM, ANVS, IMMX, CALC, AEON, ELDN, CKPT, KZR, EGRX, and BLRX
Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Reneo Pharmaceuticals (RPHM), Annovis Bio (ANVS), Immix Biopharma (IMMX), CalciMedica (CALC), AEON Biopharma (AEON), Eledon Pharmaceuticals (ELDN), Checkpoint Therapeutics (CKPT), Kezar Life Sciences (KZR), Eagle Pharmaceuticals (EGRX), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical preparations" industry.
Reneo Pharmaceuticals (NASDAQ:RPHM) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.
91.0% of Reneo Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 17.9% of Reneo Pharmaceuticals shares are owned by company insiders. Comparatively, 20.7% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Reneo Pharmaceuticals presently has a consensus target price of $18.14, indicating a potential upside of 902.07%. Given Celularity's higher possible upside, equities analysts clearly believe Reneo Pharmaceuticals is more favorable than Celularity.
Reneo Pharmaceuticals received 12 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 58.82% of users gave Reneo Pharmaceuticals an outperform vote while only 42.11% of users gave Celularity an outperform vote.
Celularity has higher revenue and earnings than Reneo Pharmaceuticals.
Reneo Pharmaceuticals has a net margin of 0.00% compared to Reneo Pharmaceuticals' net margin of -1,226.72%. Reneo Pharmaceuticals' return on equity of 30.79% beat Celularity's return on equity.
In the previous week, Reneo Pharmaceuticals had 8 more articles in the media than Celularity. MarketBeat recorded 11 mentions for Reneo Pharmaceuticals and 3 mentions for Celularity. Reneo Pharmaceuticals' average media sentiment score of 0.91 beat Celularity's score of 0.46 indicating that Celularity is being referred to more favorably in the news media.
Reneo Pharmaceuticals has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.
Summary
Celularity beats Reneo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Celularity News Delivered to You Automatically
Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Celularity Competitors List
Related Companies and Tools
